Chimagen Biosciences is a clinical-stage biotechnology company focused on the discovery and development of novel multi-specific T cell-engagers and NK cell-engagers for the treatment of cancer and autoimmune diseases.
The company utilizes its proprietary covalent multi-specific antibody platform, which combines rational protein engineering with patented stabilization chemistry to create therapeutics that engage multiple disease targets simultaneously. This platform supports trispecific formats with tunable target engagement, enhanced stability, and manufacturability, protected by US Patent 12,134,661 B1.
Founded in 2016 and primarily located in Chengdu, China, with additional presence in Shanghai, Chimagen operates with a global reach through partnerships and collaborations. It maintains a pipeline of over seven programs targeting validated biology in oncology and immunology, with several candidates advancing in clinical trials, including co-development efforts such as with Bioray Biopharmaceutical.
The company is privately held and venture capital-backed, having completed a Series B financing in 2024 led by Foresite Capital and Lilly Asia Ventures. It has entered into significant agreements with GSK, including the acquisition of CMG1A46 for up to $850 million in total potential value and a separate trispecific TCE for multiple myeloma announced in 2026.
Chimagen positions itself as an emerging innovator in the multi-specific antibody therapeutics space, leveraging its technology platforms to address unmet medical needs in oncology and autoimmune conditions.
Also known as Enmu Biotechnology.
Trispecific TCE binds T cells and two tumour antigens; entering Phase I in 2027; deal worth up to $750 million; designed to improve efficacy and tolerability versus current TCEs.
